Skip to main content
Discovering the causes of cancer and the means of prevention
 

COVID-19 Research by DCEG Featured in NCI Cancer Currents Blog

, by DCEG Staff

dACE2 is a new, shorter form of ACE2, the receptor SARS-CoV-2 uses to enter cells.

NCI researchers identified dACE2, a new, shorter form of ACE2, the receptor SARS-CoV-2 uses to enter cells. dACE2 is expressed in cells exposed to SARS-CoV-2 or interferon but isn't a receptor for the virus. (Created with BioRender.com)

Credit: National Cancer Institute

A recent NCI Cancer Currents blog features an interview with Ludmila Prokunina-Olsson, Ph.D., Chief of the Laboratory of Translational Genomics, about her work with an international group of experts to investigate the underlying biology of coronavirus infections. The post also describes the volunteer activities of Neelam Giri, M.D., staff clinician in the Clinical Genetics Branch, who gave her time last year to help test fellow NIH employees for SARS-CoV-2. Learn more about efforts by Dr. Prokunina-Olsson and other cancer researchers to fight against COVID-19.

< Older Post

Mentorship at DCEG: A Tradition of Excellence

Newer Post >

Laufey Aumundadottir Receives 2021 CCR-DCEG FLEX Award

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “COVID-19 Research by DCEG Featured in NCI Cancer Currents Blog was originally published by the National Cancer Institute.”